[HTML][HTML] Molnupiravir for intra-household prevention of COVID-19: the MOVe-AHEAD randomized, placebo-controlled trial
SA Alpizar, J Accini, DC Anderson, B Eysa… - Journal of Infection, 2023 - Elsevier
Objectives To evaluate the efficacy and safety of molnupiravir for intra-household post-
exposure prophylaxis (PEP) of COVID-19. Methods MOVe-AHEAD was a randomized …
exposure prophylaxis (PEP) of COVID-19. Methods MOVe-AHEAD was a randomized …
Effectiveness of molnupiravir and nirmatrelvir–ritonavir in hospitalized patients with COVID-19: a target trial emulation study
Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA. 2 wave: an observational study
Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
Objective To examine whether treatment with the antiviral agent molnupiravir during the first
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …
A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19
K Nakamura, K Fujimoto, C Hasegawa… - Clinical and …, 2022 - Wiley Online Library
Abstract Molnupiravir (MK‐4482) is an oral prodrug of the antiviral ribonucleoside analog, N‐
hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute …
hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute …
Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19
The COVID-19 pandemic needs no introduction at present. Only a few treatments are
available for this disease, including remdesivir and favipiravir. Accordingly, the …
available for this disease, including remdesivir and favipiravir. Accordingly, the …
Outpatient treatment of confirmed COVID-19: a living, rapid evidence review for the American College of Physicians (Version 2)
Background: Clinicians and patients want to know the benefits and harms of outpatient
treatment options for the Omicron variant of SARS-CoV-2. Purpose: To assess the benefits …
treatment options for the Omicron variant of SARS-CoV-2. Purpose: To assess the benefits …
[HTML][HTML] The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era
The quest for effective drugs to treat COVID-19 has been a priority since the outbreak of the
disease. The clinical application of remdesivir has been greatly restricted by the need for …
disease. The clinical application of remdesivir has been greatly restricted by the need for …
Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
Y Suzuki, Y Shibata, H Minemura, T Nikaido… - Clinical and …, 2023 - Springer
It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …
Molnupiravir: first approval
YY Syed - Drugs, 2022 - Springer
Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …